Alexandra Green

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

Adeodata Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, Cissy Kityo et autres

BACKGROUND: Short-cycle antiretroviral therapy (ART), comprising 5 days on and 2 days off treatment, offers the potential for ART-free weekends, reduced toxicity, and improved quality of life for adolescents living with HIV, who typically have worse treatment outcomes than other age groups. …

Ouganda, gb, Zimbabwe, Kenya, Afrique du Sud, it, ca, nl (code pays fourni par la source)

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

Background Alternatives to daily oral antiretroviral therapy (ART) are important for adolescents with HIV (AHIV) to improve adherence and outcomes. Long-Acting-injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) has demonstrated excellent efficacy and safety and strong patient preference in adults. Methods LATA is an ongoing randomised, …

Ouganda, gb, Kenya, Zimbabwe, Afrique du Sud, it, nl (code pays fourni par la source)

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

BACKGROUND: Alternatives to daily oral antiretroviral therapy (ART) are important for adolescents with HIV (AHIV) to improve adherence and outcomes. Long-Acting-injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) has demonstrated excellent efficacy and safety and strong patient preference in adults. METHODS: LATA is an ongoing randomised, …

Ouganda, gb, Kenya, Zimbabwe, Afrique du Sud, it, nl (code pays fourni par la source)

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

Compositional Analysis of Glass Beads from Borneo and Java

Alison Carter, Barbie Campbell Cole, Alexandra Green

In this paper, we present the results from compositional analysis of heirloom glass beads from the island of Borneo and Java, Indonesia. A large portion of the beads in this study are from Borneo and housed in the British Museum’s collections. A …

Letter: Identifying the Need for Palliative Care in Patients with Refractory Gastroparesis

Simran Kripalani, Alexandra Green, Cherie P. Erkmen

us (code pays fourni par la source)

BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa

Fredrick Katongole, Angus Jennings, Constantine Mutata, Patrick Ssebunya et autres

BACKGROUND: Novel strategies to improve ART adherence, retention in care and quality of life among adolescents living with HIV (ALHIV) are needed. Short-Cycle Therapy (SCT) with 4/5 sequential days on ART, 2/3 days off ART per week has shown non-inferior virological outcomes …

Ouganda, Afrique du Sud, gb, Zimbabwe, Kenya, it (code pays fourni par la source)

Implementing Online Training for “Animal Disease Detectives” in the Asia-Pacific Region: A Focus Group Study

Annette Burgess, Harish Chandra Tiwari, Alexandra Green, Jenny‐Ann Toribio et autres

There is an identified need to strengthen the field epidemiology workforce training in the Asia-Pacific region. In response, the Asia Pacific Consortium of Veterinary Epidemiology (APCOVE) developed an online training program consisting of 36 modules delivered asynchronously and synchronously across 6 months …

au, nz, fr (code pays fourni par la source)

BREATHER Plus Clinical Trial Design: A Randomised Non-Inferiority Trial Evaluating the Efficacy, Safety and Acceptability of Short Cycle (Five Days on, Two Days Off) Dolutegravir/Tenofovir-Based Triple Antiretroviral Therapy (Art) Compared to Daily Art in Virologically Suppressed Adolescents Living with HIV Aged 12 to <20 Years in Sub-Saharan Africa

Fredrick Katongole, Angus Jennings, Constantine Mutata, Patrick Ssebunya et autres

ca, gb, Kenya, Ouganda, Afrique du Sud, it, us (code pays fourni par la source)

Short-Cycle Therapy (Weekends-Off) on Dolutegravir-Based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Randomised, Open-Label, 96-Week Non-Inferiority Trial

Adeodata Kekitiinwa, Angus Jennings, Mutsa Bwakura‐Dangarembizi, Cissy Kityo et autres

us, Ouganda, gb, Zimbabwe, Kenya, Afrique du Sud, it, ca, nl (code pays fourni par la source)

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

Ouganda, Kenya, ca, gb, Zimbabwe, Afrique du Sud, it, us, nl (code pays fourni par la source)

Ethics of Dialysis in People with Advanced Kidney Disease Who Inject Drugs

Rachel Emily Brobst, Jean Lee, Alexandra Green, Suzanne Boyle

Background: Barriers such as unstable housing, lack of insurance, and social stigma make it challenging to secure outpatient dialysis for people who inject drugs (PWID) with advanced kidney disease. We describe four cases from our center and propose a bioethical framework for …

us (code pays fourni par la source)